The development of resistant hepatitis B virus (HBV) strains during lamivudine treatment has been described repeatedly. To investigate whether the development of such resistant HBV strains can be predicted in an early phase of therapy, the HBV loads of 11 renal transplantation patients were screened at 3-month intervals by a quantitative HBV polymerase chain reaction (PCR) assay. Lamivudine resistance was detected by sequence analysis. Five patients developed resistance to lamivudine in the 12-15-month follow-up period. In all of them, a virus load of HBV DNA copies still was detectable after 3 months of therapy. This was statistically 3 1 ϫ 10 significantly different from those patients who did not develop lamivudine resistance within the observation period, all of whom had no HBV DNA detectable after 3 months of treatment ( ). Thus, virus load testing by use of a sensitive PCR assay allows the early prediction P = .0022 of the emergence of lamivudine-resistant HBV strains.
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Lamivudine is a nucleoside analogue that acts as a powerful inhibitor of hepatitis B virus (HBV) replication by interfering with the viral reverse transcriptase [1] . It has been shown repeatedly that the use of lamivudine to treat chronic HBV infection leads to a significant decrease in HBV levels in the patient's serum [2, 3] without causing serious side effects. However, it also has been observed that, during the course of lamivudine treatment, mutations in the HBV polymerase gene may develop, leading to resistance against the drug [4, 5] and to a breakthrough of HBV to high serum levels again.
Lamivudine resistance has been shown to occur in ∼14% of patients with chronic HBV infection [6] and in 27% of liver transplantation patients [3] and clearly was associated with certain patterns of mutations, all of which include either a MetrIle or a MetrVal mutation at codon 552 of the HBV polymerase gene [7, 8] . These codon 552 mutations, which are similar to the mutations detected in lamivudine-resistant human immunodeficiency virus (HIV) strains, lead to a change in the YMDD motif of the HBV polymerase, and apparently this is the molecular basis of lamivudine resistance.
Although no standard alternative therapy has been established yet, several mostly in vitro studies have shown synergistic effects with the use of combinations of nucleoside agents against HBV replication [9] [10] [11] , as well as with a combination therapy with lamivudine and HBV immune globulin [12] .
The aim of our study was to determine whether it is possible to predict the development of lamivudine-resistant HBV strains in individual patients by continuous monitoring of the patient's serum HBV load by use of a sensitive quantitative polymerase chain reaction (PCR) assay during the course of therapy.
Materials and Methods
Eleven patients (9 men and 2 women; mean age, 45.2 years; range, 24-68) with chronic HBV infection were included in the study. All had received a renal transplant between 18 months and 13 years before the start of our study and were receiving immunosuppressive therapy with a regimen that included cyclosporine and/or steroids. Seven patients were treated with lamivudine at 100 mg/day for a period of at least 12 months, and 4 patients were started on a reduced dosage according to graft function, without significant dosage reduction throughout the study period. Liver enzyme levels were normal throughout the study in all patients, with the exception of 1, in whom a 5-fold elevation of aspartate aminotransferase levels at baseline normalized during therapy. Hepatitis B e antigen (investigated by enzymun-test Hbe-Ag ϩ Anti-HBe; Roche Diagnostics, Basel, Switzerland) was detectable in 9 of the patients at the start of therapy.
The patients' virus loads were determined at the onset of therapy and at 3-month intervals for up to 12-15 months or until a resistant HBV strain was detected. For quantitative detection of the HBV DNA load in serum, viral DNA was purified from 200 mL of serum by use of spin columns and reagents from a kit (QIAamp DNA Blood Minikit; Qiagen, Chatsworth, CA). PCR was done with a set of primers described elsewhere [13] (sense primer, 5 -GCGGG-ATCCACTGTTCAAGCCTCCAAGCT-3 ; antisense primer, 5 -GCGAAGCTTAAGGAAAGAAGTCAGAAGG-3 ), to amplify a conserved region of the core gene. The antisense primer carried at its 5 -terminus a fluorescent dye label, to allow detection of the PCR products on a sequencer (ABI 373A; Applied Biosystems, Foster City, CA) with specific software (GENESCAN; Perkin Elmer, Foster City, CA). For DNA quantification, a log dilution series of the sample was prepared and a constant amount of internal standard DNA (corresponding to a concentration of 10 5 molecules/ mL) was added to each dilution for coamplification in the PCR reaction. This internal standard had been generated as a synthetic DNA fragment cloned into the unique SalI restriction site of pBR322. PCR amplification of this internal standard with the primers mentioned above yields an amplification product that is 16 bp smaller (120 bp vs. 136 bp) than that obtained from HBV DNA, and, thus, the two PCR products could easily be distinguished on the sequencer. Comparison of the amounts of these products obtained in the same reaction, as determined by the measurement of their fluorescence, allowed the concentration of HBV DNA in the original sample to be calculated.
For detection of resistant HBV strains, the polymerase gene of the HBV genome was analyzed at the start of therapy, as well as in the follow-up samples in which viral DNA was detectable, beginning at month 6 of treatment. Amplification of the HBV polymerase gene for sequence analysis was done with the primers published by Bartholomew et al. [5] . After PCR, the amplified fragments were purified on columns (Chroma Spin 100; Clontech, Palo Alto, CA) and then subjected to ethanol precipitation. The sequencing reaction was done with a cycle sequencing kit (Big Dye Terminator; Applied Biosystems), and the sequence analysis was done on a DNA sequencer (model 310; Applied Biosystems). Sequence comparisons were done with the aid of a program (Abi Prism AutoAssembler; Perkin Elmer).
Results
Virus levels at the onset of therapy and resistance data for the 11 patients included in the study are presented in table 1. At the start of treatment, only wild-type HBV sequences were detected in the serum samples of the 11 patients, and only wildtype sequences were detected at month 6 of therapy. In the further course of follow-up, 5 (45.5%) of the 11 patients developed lamivudine-resistant HBV strains. As shown in table 1, mutations indicative of lamivudine resistance became detectable in the patients between the 9th and 15th month after onset of treatment. All the patients harbored HBV strains that contained a typical resistance pattern that consists of M552V and L528M mutations, which are known to cause an ∼300-fold reduction in sensitivity to lamivudine. Comparison of the HBV polymerase amino acid sequences obtained at the start and end of follow-up from the 5 patients who developed lamivudineresistant HBV strains indicated no additional amino acid changes in the genomic region amplified by the PCR assay, with the exception of 1 case (patient 2), in which an additional V521L mutation, previously described by Bartholomew et al. [5] , was detected.
The levels of HBV DNA detected by the quantitative HBV PCR assay during the course of therapy are shown in figure  1A for the patients who developed lamivudine resistance and in figure 1B for those for whom no evidence of resistance was found during follow-up.
The amount of virus at the start of therapy varied within the resistant and nonresistant patient groups. However, both patients with a virus level 110 8 copies/mL at the onset of therapy developed resistant HBV strains during follow-up (table 1 and figure 1 ). As shown in figure 1 , in all but 1 patient HBV DNA levels decreased to below the detection level of the PCR assay ( HBV genome copies/mL of serum) during the 6-8 3 1 ϫ 10 months of lamivudine treatment. However, this decrease in the virus load to !10 3 HBV DNA copies always was slower in the patients who developed HBV resistance in the follow-up period ( figure 1A ). In particular, none of these patients was HBV DNA-negative after 3 months of therapy. This was in contrast to the nonresistant patient group (figure 1B), in which viral DNA in all the patients already was below the PCR detection limit 3 months after the onset of therapy. This difference between the 2 groups was statistically highly significant (P = , Fisher's exact 2-sided test). .0022
Discussion
It has been shown repeatedly that drug-resistant HBV strains may emerge in patients with chronic hepatitis who are treated with lamivudine in the posttransplantation setting [4, 5] . This also was shown in our study; in 5 of 11 renal transplantation patients, HBV strains carrying the lamivudine resistance mutations at the YMDD locus emerged during 12-15 months of lamivudine therapy. The rate of resistance development in this patient group is higher than that described elsewhere for nontransplantation patients [6] , probably because of the immunosuppressive therapy that the patients in our study received. Because of the limited number of patients, however, conclusions regarding resistance development in renal transplantation patients cannot be drawn yet.
The aim of our study was to find out whether a prediction of the development of such drug-resistant HBV variants is possible by measuring the HBV DNA level at the start and during the course of lamivudine therapy. In the patient group we studied, there was a wide variation in virus levels at the start of therapy within the resistant and the nonresistant patient groups. However, it is noteworthy that both patients with high starting virus levels of 110 8 copies/mL developed lamivudine-resistant HBV strains during follow-up. This would support the finding of Mutimer et al. [14] , who reported recently that the emergence of resistant virus is related to the serum HBV titer at the onset of therapy. Thus, patients with high pretreatment HBV DNA levels in serum seem to be at a high risk for developing resistant HBV strains during long-term lamivudine therapy.
The most significant finding of this study, however, was the statistically significant difference in HBV DNA levels after 3 months of follow-up between patients who developed resistant HBV strains during treatment and those who did not. All patients in whom later drug-resistant virus emerged still had detectable virus levels of 10 3 -10 5 HBV copies/mL of serum at that time, whereas patients who did not develop lamivudine-resistant HBV variants during follow-up had no detectable level of virus in serum, by PCR, after 3 months of therapy. Thus, we conclude that the level of HBV DNA after 3 months of treatment is a significant predictor of the development of lamivudine resistance. Our findings suggest that an immediate, strong restriction of viral replication is crucial for avoiding the development of resistant virus. One obvious reason for a lack of virus suppression after 3 months of therapy might be a high starting level of HBV DNA, which was the case in 2 patients. In the 3 patients who developed lamivudine-resistant virus strains despite a lower starting virus level, the reasons for the slower suppression of HBV replication by lamivudine are not clear, but pharmacologic factors leading to suboptimal drug levels in the patients may have to be considered.
Although it has been shown repeatedly that HBV strains with mutations in the YMDD region of the polymerase gene are resistant to treatment with lamivudine, the clinical significance of the emergence of such HBV strains still is controversial [15] and remains to be elucidated further.
Finally, our data show that a continuous monitoring of the HBV level in the serum of patients undergoing lamivudine treatment, by use of a sensitive and quantitative PCR assay, is an important tool for predicting the development of drug-resistant HBV strains within 15 months of the onset of therapy. In the future, HBV DNA monitoring possibly could be used to identify candidates for early initiation of combination therapy schemes that currently are under investigation.
